| 1. |
- Eriksson, T., et al.
(författare)
-
Sibbaldia: a molecular phylogenetic study of a remarkably polyphyletic genus in Rosaceae
- 2015
-
Ingår i: Plant Systematics and Evolution. - : Springer Science and Business Media LLC. - 0378-2697 .- 2199-6881 .- 1615-6110. ; 301:1, s. 171-184
-
Tidskriftsartikel (refereegranskat)abstract
- Using DNA sequence data from nuclear ribosomal ITS in combination with plastid trnLF spacer and trnL intron data, we show that Sibbaldia is a polyphyletic assemblage. It falls into five separate clades of Potentilleae, three within Fragariinae and two within Potentilla (Potentillinae sensu Sojak). To a large extent, our results are congruent with Sojak's findings based on morphological characters such as anther structure. Four of the Sibbaldia species included in this study remain in Sibbaldia, while S. adpressa is classified in Sibbaldianthe, S. perpusilloides is considered to represent a new genus in Fragariinae, Chamaecallis Smedmark, S. micropetala is nested within the Potentilla anserina clade, and four species belong to a basal clade of Potentilla. The phylogenetic affinity of Sibbaldiopsis is still unsettled, but one of the three species that have been classified in the genus is found to belong inside Sibbaldia, and it should be named Sibbaldia retusa (O.F. Muller) T. Erikss. Further study will show whether the remaining two species, Potentilla cuneifolia and P. miyabei, are more closely related to Sibbaldia, Sibbaldianthe, or if they make up a distinct lineage separate from either of these.
|
|
| 2. |
|
|
| 3. |
- Hao, S, et al.
(författare)
-
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
- 2023
-
Ingår i: JAMA oncology. - : American Medical Association (AMA). - 2374-2445 .- 2374-2437. ; 9:1, s. 88-94
-
Tidskriftsartikel (refereegranskat)abstract
- The combination of prostate-specific antigen (PSA) testing with magnetic resonance imaging (MRI) for prostate cancer detection has rarely been evaluated in a screening context. The STHLM3-MRI screening-by-invitation study (NCT03377881) has reported the benefits of using MRI with subsequent combined targeted and standard biopsies compared with using standard biopsies alone.ObjectiveTo investigate the cost-effectiveness of prostate cancer screening using MRI with combined targeted and standard biopsies compared with standard biopsies alone among men aged 55 to 69 years in Sweden, based on evidence from the STHLM3-MRI study.Design, Setting, and ParticipantsThis economic evaluation study was conducted from a lifetime health care perspective using a microsimulation model to evaluate no screening and screening strategies among adult men in Sweden. Men aged 55 to 69 years in Sweden were simulated for no screening and screening strategies. Input parameters were obtained from the STHLM3-MRI study and recent reviews. One-way and probabilistic sensitivity analyses were performed in May 2022.InterventionsNo screening, quadrennial PSA screening using standard biopsies alone, and MRI-based screening using combined targeted and standard biopsies.Main Outcomes and MeasuresThe number of tests, incidence, deaths, costs, quality-adjusted life-years (QALY), and incremental cost-effectiveness ratios (ICERs) were estimated.ResultsA total 603 men were randomized to the standard arm, 165 of these participants (27.4%) did not undergo standard biopsy; 929 men were randomized to the experimental arm, 111 (11.9%) of whom did undergo MRI or any biopsy. Compared with no screening, the screening strategies were associated with reduced lifetime prostate cancer–related deaths by 6% to 9%. Screening with MRI and the combined biopsies resulted in an ICER of US $53 736, which is classified as a moderate cost per QALY gained in Sweden. Relative to screening with standard biopsies alone, MRI-based screening reduced the number of both lifetime biopsies and overdiagnosis by approximately 50% and had a high probability of being cost-effective than the traditional PSA screening.Conclusions and RelevanceFor prostate cancer screening, this economic evaluation study found that PSA testing followed by MRI with subsequent combined targeted and standard biopsies had a high probability to be more cost-effective compared with the traditional screening pathway using PSA and standard biopsy. MRI-based screening may be considered for early detection of prostate cancer in Sweden.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
